AstraZeneca AZN reported mixed phase 3 data for datopotamab deruxtecan in lung cancer, but we don’t see the data as having a major impact on the firm’s fair value or wide moat. The cancer treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results